← Back to all trials
Completed
NCT05397132
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
Conditions: Hematologic Malignancy
Sex: All
Ages: 18 Years – N/A
Enrollment: 88
Sponsor: Duke University
Location: Duke University Durham North Carolina
Summary
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.
Eligibility Criteria
Inclusion Criteria:
1. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
2. Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product.
3. Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study.
Exclusion Criteria:
* NA
Source: ClinicalTrials.gov (NCT05397132). StuddyBuddy aggregates publicly available trial information.
